The presence of occult carcinoma cells in BM, PB, or AP of patients (pts) with breast cancer may have important therapeutic and prognostic implications. We examined BM (n=5), PB (n=9) and AP (n=10) of 11 pts receiving sequential dose intensive chemotherapy and either positively selected (Ceprate SC columns, Cell Pro, Bothell, WA, USA) or unselected PBPC support. Immunochemistry using anticytokeratin antibodies (A45/B.B3, Micromet, Munich, Germany) and APAAP-staining technique was applied. 1,8 × 10 6 cells were evaluated from each individual patient sample prior to start of chemotherapy. 2/5 BM aspirates, 5/9 PB samples and 5/10 AP products but only 1/6 positively selected AP products showed cytokeratin positive cells. All 3 sample sources were examined in 4 pts (1 pt: 3 samples negative, 2 pts: 2 samples positive, 1 pt: 1 sample positive). In 5 pts 2 sample sources were studied (1 pt: 2 samples negative, 2 pts: 2 samples positive, 2 pts: 1 sample positive and 1 negative. In only 2 pts all studied sample sources were negative whereas in the other 9 pts at least one sample source showed cytokeratin positive cells. We conclude that pts with metastatic breast cancer have a high rate of tumor cell contamination and examination of larger cell numbers per sample especially using tumor cell selection techniques may be warranted to get consistent results between different sample sources. The aim of this study was to establish sensitive techniques for the detection of residual germ cell tumor cells in peripheral blood and progenitor cell harvests. For this purpose, we used immunocytochemical staining for cytokeratin filaments and reverse transcriptase-polymerase chain reaction (RT-PCR) for germ cell alkaline phosphatase (GCAP). Germ cell tumor lines Tera-1 and Tera-2 were titrated into normal peripheral blood. Immunocytochemical staining allowed detection of one cytokeratin-positive cell in 10 5 cells. RT-PCR for GCAP displayed a sensitivity of one tumor cell in 10 6 cells for Tera-1, one tumor cell in 10 4 cells for Tera-2, and no positivity in normal mononuclear cells (n=20) and progenitor cell harvests (n=5). The prospective analysis of peripheral blood and progenitor cell harvests from twenty patients with germ cell tumors revealed tumor cell contamination in three patients using immunocytochemical staining and in seven patients by RT-PCR for GCAP. Conclusion: RT-PCR for GCAP is suitable for the sensitive detection of residual germ cell tumor cells in peripheral blood and progenitor cell harvests. In acute lymphoblastic leukemia (ALL) relapse after allogeneic stemcell transplantation is a major cause of treatment failure. This study was undertaken to examine the prognostic value of MRD immediately pre and post transplantation for the occurrence of early clinical relapse in ALL. MRD was examined by means of a PCR method detecting the clonespecific T-cell (or B-cell) receptor rearrangement (or IgH). The method was made quantitative by comparing the PCR reactions of DNA from patient specimens mixed with known concentrations of a DNA construct (competitor) identical to a part of the DNA coding for the clone-specific rearranged receptor. This method allowed the detection of one malignant cell among 10 5 non malignant cells and it enabled a quantitative estimate of the malignant cell concentration.
S145

480
Since May 1998 seven ALL patients have been examined (1 HLAid sibling; 6 MUD). In five patients the malignant clones have been detectable after BMT, and so far clinical relapses have occurred in two of these. In three patients attempts to reverse an increasing concentration of malignant cells have been performed by early cessation of immunopressive drugs or by infusion of donor leucocytes (DLI).
The presented data show that quantitation of MRD by means of PCR is a powerful tool for the detection of an imminent relapse after BMT. Furthermore, this method can be used to monitor and graduate an attempt to increase the graft-versus-leukemia (GVL) effect caused by reduction of immuno-suppression and/or by DLI. The detection of tumor cells by immunocytochemistry (ICC) was carried out on 28 leukaphereses (LP) and 21 bone marrows (BM) from 27 patients with SCLC. In limited disease (LD), 4 of 16 LP and 3/10 BM had tumor cells detected by ICC and 6 of 12 LP and 9/11 BM in extensive disease (ED). In BM, cells expressed MOC-1, MOC-52, MOC-31 antigens and were heterogeneous for anti-cytokeratins (CK), but in LP, tumor cells lacked MOC-31 and CK antigen expression. To evaluate the expansion and development of tumor cells, 7/8 LP (4 ED, 4 LD), 2 BM (ED) and eight controls (4 LP from breast cancer and 4 cord blood) were cultured. We enriched tumor cells by removal of CD45 + cells. Mononuclear and enriched tumor cells were cultured in the presence of 5 cytokines using SCF (100 and 10 ng/ml) in plasma or serum (+/−) in RPMI and a commercially made medium for ex-vivo expansion of hematopoietic stem cells (serum free). The results show that tumor cells were capable of in vitro growth in all conditions. In BM giant clusters were seen till day 35. LP from 7 ICC + patients also had tumor cells in culture. On day 5, tumor cells increased (40-100 fold) and were detectable until day 13. Unexpectedly, the tumor cells in LP reexpressed MOC-31 antigen as shown by ICC, flow cytometry and clonogenic assays, but were also MOC-1 + , MOC-52 + and negative for hematopoietic cell antigens. In BM, tumor cells were positive for c-kit receptor at day 0 and during expansion. These conditions permitted the expansion of tumor cells, therefore, we emphasize the need for careful consideration when expanding hematopoietic cells.
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